William P Tew

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
  2. ncbi Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Curr Treat Options Oncol 14:1-11. 2013
  3. ncbi Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
  4. ncbi Ovarian cancer in older women
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 35:582-9. 2008
  5. ncbi Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:621-4. 2012
  6. ncbi Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
    John P Diaz
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:335-9. 2010
  7. ncbi The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
  8. ncbi A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
  9. ncbi Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
  10. ncbi Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 106:381-7. 2007

Collaborators

Detail Information

Publications19

  1. ncbi Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  2. ncbi Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Curr Treat Options Oncol 14:1-11. 2013
    ..As the field of geriatric oncology evolves and prospective trials tailored to older women with ovarian cancer are developed, specific guidelines will ultimately assist in these difficult decisions...
  3. ncbi Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
    ..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent...
  4. ncbi Ovarian cancer in older women
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 35:582-9. 2008
    ....
  5. ncbi Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:621-4. 2012
    ..We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen...
  6. ncbi Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
    John P Diaz
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:335-9. 2010
    ..The objective of this study was to examine the incidence and management of bevacizumab-associated gastrointestinal (GI) perforations in patients with recurrent ovarian carcinoma...
  7. ncbi The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  8. ncbi A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  9. ncbi Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  10. ncbi Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 106:381-7. 2007
    ..The objective of this study was to compare the response to platinum-taxane chemotherapy and subsequent outcomes between patients older and younger than 65 years of age with stages IIIC-IV epithelial ovarian cancer (EOC)...
  11. ncbi Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 111:265-70. 2008
    ..The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer...
  12. ncbi Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  13. ncbi Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer
    Karin K Shih
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 128:535-9. 2013
    ..The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with or without chemotherapy in high-risk endometrial cancer...
  14. ncbi A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer
    Dennis S Chi
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncologist 14:835-9. 2009
    ..To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer...
  15. ncbi Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience
    Aliza L Leiser
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 105:657-61. 2007
    ....
  16. ncbi Use of complementary medications among older adults with cancer
    Ronald J Maggiore
    Department of Medicine, Sections of Geriatrics Palliative Medicine and Hematology Oncology, University of Chicago Medical Center, Chicago, Illinois, USA
    Cancer 118:4815-23. 2012
    ..The objective of this study was to evaluate the prevalence of complementary medication use and to identify the factors associated with its use among older adults with cancer...
  17. ncbi Targeted therapies for esophageal cancer
    William P Tew
    Memorial Sloan-Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Oncologist 10:590-601. 2005
    ..This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma...
  18. ncbi Doublet chemotherapy in the elderly patient with ovarian cancer
    Min Y Teo
    Department of Medical Oncology, Cork Mercy University Hospitals, Cork, Ireland
    Oncologist 17:1450-60. 2012
    ..Geriatric assessment is an important component of decision making. Prospective studies are needed to develop strategies to determine the optimal treatment for older patients with ovarian cancer...
  19. ncbi Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....